PSY38 COST-EFFECTIVENESS OF GOLIMUMAB IN ANKYLOSING SPONDYLITIS FROM THE UK PAYER PERSPECTIVE

Introduction Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective.